id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-E-0039-0002,FDA,FDA-2002-E-0039,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-07-28T04:00:00Z,2003,7,,,2025-09-30T23:43:38Z,,0,0,090000648048b383
FDA-2002-E-0039-0001,FDA,FDA-2002-E-0039,Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,General Notice,2002-11-20T05:00:00Z,2002,11,2002-11-18T05:00:00Z,,2025-09-30T23:40:55Z,02-29187,0,0,090000648048b33a